Mannose ameliorates experimental colitis by protecting intestinal barrier integrity
Lijun Dong, Jingwen Xie, Youyi Wang, Honglian Jiang, Kai Chen, Dantong Li, Jing Wang, Yunzhi Liu, Jia He, Jia Zhou, Liyun Zhang, Xiao Lu, Xiaoming Zou, Xiang‐Yang Wang, Qingqing Wang, Zhengliang Chen, Daming Zuo
Abstract
Metabolite alteration has been associated with the pathogenesis of inflammatory bowel disease (IBD), including colitis. Mannose, a natural bioactive monosaccharide that is involved in metabolism and synthesis of glycoproteins, exhibits anti-inflammatory and anti-oxidative activities. We show here that the circulating level of mannose is increased in patients with IBD and mice with experimental colitis. Mannose treatment attenuates intestinal barrier damage in two mouse colitis models, dextran sodium sulfate (DSS)-induced colitis and spontaneous colitis in IL-10-deficient mice. We demonstrate that mannose treatment enhanced lysosomal integrity and limited the release of cathepsin B, preventing mitochondrial dysfunction and myosin light chain kinase (MLCK)-induced tight junction disruption in the context of intestinal epithelial damage. Mannose exerts a synergistic therapeutic effect with mesalamine on mouse colitis. Cumulatively, the results indicate that mannose supplementation may be an optional approach to the treatment of colitis and other diseases associated with intestinal barrier dysfunction.